Phoenix Biotech Acquisition Stock Current Ratio
Phoenix Biotech Acquisition fundamentals help investors to digest information that contributes to Phoenix Biotech's financial success or failures. It also enables traders to predict the movement of Phoenix Stock. The fundamental analysis module provides a way to measure Phoenix Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phoenix Biotech stock.
Phoenix |
Phoenix Biotech Acquisition Company Current Ratio Analysis
Phoenix Biotech's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Phoenix Biotech Current Ratio | 13.88 X |
Most of Phoenix Biotech's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phoenix Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Phoenix Biotech Acquisition has a Current Ratio of 13.88 times. This is 242.72% higher than that of the Capital Markets sector and significantly higher than that of the Financials industry. The current ratio for all United States stocks is notably lower than that of the firm.
Phoenix Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phoenix Biotech's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phoenix Biotech could also be used in its relative valuation, which is a method of valuing Phoenix Biotech by comparing valuation metrics of similar companies.Phoenix Biotech is currently under evaluation in current ratio category among its peers.
Phoenix Fundamentals
| Return On Asset | -0.0255 | |||
| Current Valuation | 66.05 M | |||
| Number Of Shares Shorted | 86 | |||
| Net Income | (2.52 M) | |||
| Cash And Equivalents | 553.77 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 650 K | |||
| Current Ratio | 13.88 X | |||
| Book Value Per Share | (2.20) X | |||
| Cash Flow From Operations | (1.71 M) | |||
| Short Ratio | 1.62 X | |||
| Beta | 0.044 | |||
| Total Asset | 42.37 M | |||
| Retained Earnings | (10.76 M) | |||
| Working Capital | 11.62 M | |||
| Z Score | -0.03 | |||
| Net Asset | 42.37 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |